Semaglutide: Difference between revisions

Line 19:

==Side effects==

While semaglutide has shown great promise in helping manage obesity, it is associated with a variety of dose-dependent side effects, as demonstrated in clinical trials. The most commonly reported adverse effects are gastrointestinal and neurological in nature. Gastrointestinal issues include nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are primarily due to semaglutide's mechanism of action, as the slowing of gastric emptying can cause discomfort, particularly at higher doses.<ref>DOI:10.1177/87551225221092681</ref>

While semaglutide has shown great promise in helping manage obesity, it is associated with a variety of dose-dependent side effects, as demonstrated in clinical trials. The most commonly reported adverse effects are gastrointestinal and neurological in nature. Gastrointestinal issues include nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are primarily due to semaglutide's mechanism of action, as the slowing of gastric emptying can cause discomfort, particularly at higher doses.<ref>DOI: 10.1177/87551225221092681</ref>

Neurological side effects, including headaches and dizziness, are also frequently reported. These may result from fluctuations in blood sugar levels and how the brain adjusts to changes in hunger and energy signaling. Other less direct effects, such as gastroenteritis, may occur due to altered gut motility or changes in gut flora, which increase susceptibility to infection. Additionally, semaglutide can affect kidney function because reduced fluid intake may lead to dehydration, highlighting the importance of monitoring hydration levels. Some users also report nasopharyngitis, potentially linked to immune modulation, though this is less common.

Line 25:

While semaglutide is effective for weight loss, these findings emphasize the need to balance therapeutic benefits with patient tolerability, tailoring treatment plans to minimize side effects while achieving optimal outcomes.

Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>~~DOI~~:~~10.1001/jamanetworkopen.2024.13172~~</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility.

Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>PMID: 38787563</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility.

== References ==

Semaglutide: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 19: / Line 19: @@
 ==Side effects==
-While semaglutide has shown great promise in helping manage obesity, it is associated with a variety of dose-dependent side effects, as demonstrated in clinical trials. The most commonly reported adverse effects are gastrointestinal and neurological in nature. Gastrointestinal issues include nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are primarily due to semaglutide's mechanism of action, as the slowing of gastric emptying can cause discomfort, particularly at higher doses.<ref>DOI:10.1177/87551225221092681</ref>
+While semaglutide has shown great promise in helping manage obesity, it is associated with a variety of dose-dependent side effects, as demonstrated in clinical trials. The most commonly reported adverse effects are gastrointestinal and neurological in nature. Gastrointestinal issues include nausea, diarrhea, vomiting, constipation, and abdominal pain. These effects are primarily due to semaglutide's mechanism of action, as the slowing of gastric emptying can cause discomfort, particularly at higher doses.<ref>DOI: 10.1177/87551225221092681</ref>
 Neurological side effects, including headaches and dizziness, are also frequently reported. These may result from fluctuations in blood sugar levels and how the brain adjusts to changes in hunger and energy signaling. Other less direct effects, such as gastroenteritis, may occur due to altered gut motility or changes in gut flora, which increase susceptibility to infection. Additionally, semaglutide can affect kidney function because reduced fluid intake may lead to dehydration, highlighting the importance of monitoring hydration levels. Some users also report nasopharyngitis, potentially linked to immune modulation, though this is less common.
@@ Line 25: / Line 25: @@
 While semaglutide is effective for weight loss, these findings emphasize the need to balance therapeutic benefits with patient tolerability, tailoring treatment plans to minimize side effects while achieving optimal outcomes.
-Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>DOI:10.1001/jamanetworkopen.2024.13172</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility.
+Semaglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight loss and glycemic control but is often discontinued due to adverse effects and financial barriers. Real-world data reveal that 36.5% of patients discontinue GLP-1 agonists within 12 months, with higher rates among those with obesity compared to type 2 diabetes<ref>PMID: 38787563</ref>. Factors such as gastrointestinal side effects, out-of-pocket costs, and demographic disparities, including race and socioeconomic status, significantly contribute to discontinuation rates (Do et al., 2024). These findings highlight the need for balancing therapeutic benefits with patient tolerability and accessibility.
 == References ==
 <references/>